Stocks to buy for long term: Brokerage firm YES Securities has identified three stocks—Entero Healthcare Solutions, Maruti Suzuki India and Lupin—as its preferred investment ideas for June 2026, citing strong sector tailwinds, improving financial performance and multiple long-term growth triggers.
The brokerage believes these companies are well-positioned to benefit from structural trends across healthcare distribution, automobiles and pharmaceuticals, while also delivering healthy earnings growth over the next 12 months.
According to the report, all three stocks carry a ‘Buy’ rating with potential upside ranging between 20% and 21% from current levels. The recommendations come at a time when investors are increasingly focusing on businesses with scalable models, strong balance sheets and clear visibility on future earnings.
YES Securities said each of these companies is benefiting from industry-wide shifts that could support sustained growth over the medium term. The brokerage highlighted improving profitability, expanding market opportunities and strategic investments as key factors underpinning its positive outlook.
: YES Securities has maintained a ‘Buy’ rating on Entero Healthcare Solutions with a target price of ₹1,402 against a current market price of ₹1,168, implying a potential upside of around 20%.
The brokerage noted that Entero has emerged as India’s largest organised pharma and MedTech distribution platform after building a nationwide network through more than 45 acquisitions and strong organic growth. Entero has consistently grown faster than the broader pharmaceutical market and is benefiting from increasing compliance requirements, procurement consolidation and GST-led formalisation, it added.
: YES Securities has assigned a target price of ₹15,745 to Maruti Suzuki India, compared with a current market price of ₹13,140, suggesting a potential upside of 20%.
The brokerage believes Maruti remains one of the strongest beneficiaries of the recovery in India’s small-car segment following the GST reduction on entry-level vehicles from 28% to 18%.YES Securities highlighted the company’s aggressive capacity expansion plans, including the Kharkhoda facility and Gujarat expansion, which together are expected to add around 5 lakh units of annual capacity in FY27. The brokerage also sees long-term potential from the company’s electric vehicle strategy, including the upcoming eVX platform and expansion of charging infrastructure.
: Among pharmaceutical stocks, YES Securities remains bullish on Lupin and has set a target price of ₹2,750 compared with its current market price of ₹2,271, indicating an upside potential of approximately 21%.
The brokerage said Lupin’s transformation from a traditional generic drug manufacturer into a complex-products-focused pharmaceutical company is beginning to reflect in its financial performance. Lupin’s US business remains its biggest earnings contributor, with revenues increasing 40% year-on-year to US$1.3 billion in FY26. YES Securities believes growth from injectables, biosimilars and respiratory therapies will support future earnings. Domestically, Lupin continues to outperform the Indian pharmaceutical market, driven by leadership positions in cardiovascular, diabetes and respiratory segments.
The brokerage pointed to strong FY26 financial performance, with revenue rising 23%, EBITDA increasing 55%, PAT surging 74% and EBITDA margins expanding to 29.7%, as evidence of the company’s improving business quality and profitability.
Disclaimer: The views and recommendations made above are those of individual analysts or broking companies, and not of Mint. We advise investors to check with certified experts before making any investment decisions.